Call for Papers

Biologics: Targets and Therapy is indexed online:

• PubMed Central (Biologics)
• American Chemical Society's 'Chemical Abstracts Service' (CAS)
• Embase, Scopus and the Elsevier Bibliographic databases
• Directory of Open Access Journals (DOAJ)
• OAIster: The Open Access Initiative
• ResearchGATE scientific network
  
   

What is the advantage to you of publishing in Biologics: Targets & Therapy?

• It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
• Although Biologics: Targets & Therapy receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish. 
• The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Biologics: Targets & Therapy has one of the fastest turnaround times of any medical journal in the world. Generally peer review is complete within 2-3 weeks and the editor’s decision within 24 hours of this. It is therefore very rare to have to wait more than 4 weeks for a final decision. 
• Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution a publication processing fee.

PubMed Central

Biologics: Targets & Therapy is indexed on PubMed Central. All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits

If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so.  Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page, you'll just need to supply the working title of your next paper and when you intend to submit by.

Yours sincerely

Professor Doris Mangiaracina Benbrook

Editor-in-Chief
Biologics: Targets & Therapy
Email: editor-in-chief@dovepress.com